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Objective: To investigate whether cardiac expression of the nuclear peroxisome proliferator-activated receptor a (PPARa) is altered in
patients with hypertensive heart disease (HHD).
Methods: We studied endomyocardial septal biopsies from 24 patients with essential hypertension divided into three groups: 6 without left
ventricular hypertrophy (LVH) (HT group), 10 with LVH (LVH group), and 8 with LVH and heart failure (HF) (HF group). The expression of
two PPARa isoforms (the native active and the truncated inhibitory) was analyzed by Western blot and reverse transcription polymerase
chain reaction (RT–PCR), and two PPARa target genes were evaluated by RT–PCR. Histomorphological features were evaluated in a
second myocardial sample from LVH and HF groups.
Results: Whereas the expression of native PPARa protein was lower ( p <0.05) in LVH and HF groups than in the HT group, truncated
PPARa protein was overexpressed ( p <0.001) in the HF group as compared with LVH and HT groups. The mRNA expression of native and
truncated PPARa was similar in the three groups of hypertensives. In addition, a progressive decrease ( p for trend<0.05) in the two PPARa
target genes mRNA expression was observed among HT, LVH and HF groups. The amount of truncated PPARa protein correlates directly
with cardiomyocytes apoptosis and inversely with cardiomyocytes density in patients with HHD. In addition, the expression of truncated
PPARa protein was directly correlated with left ventricular volumes, and inversely with ejection fraction in all hypertensives.
Conclusions: These findings suggest that post-transcriptional regulation of PPARa isoforms is altered in patients with HHD, namely in
those developing HF. An excess of the truncated inhibitory isoform may be involved in hypertensive left ventricular failure and remodeling.
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doi:10.1016/j.cardiores.2005.11.016
* Corresponding author. Division of Cardiovascular Sciences, Centre for
Applied Medical Research, University of Navarra, CIMA, Avda. Pı´o XII
55, 31008 Pamplona, Spain. Tel.: +34 948194700x3000; fax: +34
948194716.
E-mail address: jadimar@unav.es (J. Dı´ez).
1 The first two authors (Marı´a J. Goikoetxea and F. Javier Beaumont)
contributed equally to this work.1. Introduction
Previous studies have shown that myocardial fatty acid
utilization is decreased in the failing heart of spontaneously
hypertensive rats [1,2] and patients with essential hyperten-
sion [3]. It has also been shown that expression of genes
encoding cardiac fatty acid oxidation enzymes is coordi-
nately repressed in the myocardium of hypertensive rats and
patients with heart failure (HF) [4]. This defect in lipid
metabolism can be regarded as a result of alterations in69 (2006) 899 – 907d by Elsevier B.V. All rights reserved.
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 peroxisome proliferator-activated receptor a (PPARa) tran-
scription factor activity. An abnormally low expression of
several fatty acid transporters and mitochondrial fatty acid-
metabolizing enzymes has been found in the heart of
PPARa null mice [5]. Thus PPARa seems to be a critical
regulator of myocardial energetics, through the activation of
some genes encoding key limiting steps in the fatty acid
utilization pathway [6]. Moreover, recent evidences suggest
that PPARa may be an antiinflammatory and antifibrotic
transcription factor [7–10]. In fact, the heart from PPARa-
null mice shows progressive myocardial degeneration
associated with contraction band necrosis, inflammatory
infiltrates and diffuse fibrosis besides an abnormally low
expression of several fatty acid transporters and mitochon-
drial fatty acid-metabolizing enzymes [5].
Two variants of the human PPARa transcription factor
have been described. Tugwood et al. [11] and Palmer et al.
[12] found a splice variant of PPARa mRNA lacking exon 6
in human liver. Later on, this variant was also reported in
other human tissues including the heart [13]. Whereas the
native PPARa mRNA is known to give rise to an active
PPARa protein (53 kDa), the truncated PPARa mRNA
gives rise to a form of PPARa protein (30 kDa) which lacks
the ligand-binding domain [14]. In addition, recent findings
suggest that, upon nuclear translocation, the truncated
isoform of PPARa exerts repressive action on the native
PPARa function, probably through competition for essential
coactivators [14].
We have hypothesized that an imbalance between the
native active and the truncated inhibitory isoforms of
PPARa may occur in patients with hypertensive heart
disease (HHD). This study was therefore designed to
investigate the expression of PPARa isoforms and the
obligate heterodimeric partner retinoid X receptor a
(RXRa) in the myocardium of patients with HHD. In
addition, the expression of PPARa target genes involved in
fatty acid oxidation and histomorphological features of
myocardial remodeling were also assessed in tissue samples
from the same patients.20122. Methods
2.1. Patients
All subjects gave written informed consent to participate
in the study, and the institutional review committee
approved the protocol. The study was approved by the
ethical committee of Donostia University Hospital and
conformed to the principles of the Helsinki Declaration.
The hypertensive population consisted of 24 Caucasian
patients with systolic blood pressure >139 and/or diastolic
blood pressure of >89 mm Hg. All patients had appropriate
clinical and laboratory evaluation to exclude secondary
hypertension. Other cardiac diseases (e.g., coronary artery
disease, aortic stenosis, hypertrophic cardiomyopathy) wereexcluded after complete medical examination, which in-
cluded a diagnostic cardiac catheterization. Patients with
diabetes mellitus or metabolic syndrome, as defined by the
ATPIII criteria, were excluded from the study [15].
Whereas 18 patients exhibited HHD, 6 patients did not
(HT group). HHD was defined by the presence of left
ventricular hypertrophy (LVH) in the echocardiogram (see
below) in the absence of a cause other than arterial
hypertension. Whereas 10 patients with HHD did not
present medical history or current manifestations of HF
(LVH group), 8 patients with HHD had a previous diagnosis
of HF (HF group). The diagnosis of HF was made on a
clinical basis, by the presence of, at least, 1 major and 2
minor Framingham criteria [16]. After echocardiographic
evaluation (see below) the patients were classified into two
groups: 4 patients exhibiting an ejection fraction (EF)<0.40
(i.e. patients with systolic HF) and 4 patients presenting an
EF0.40 (i.e. patients with diastolic HF). Furthermore,
hemodynamic evidence of myocardial failure was obtained
in each patient by measuring elevated left ventricular end-
diastolic pressure and pulmonary capillary wedge pressure
(>12 mm Hg in both cases).
2.2. Assessment of left ventricular dimensions, mass and
function
2D echocardiographic imaging, targeted M-mode record-
ings and Doppler ultrasound measurements were obtained in
each patient. Left ventricular end-diastolic and end-systolic
volumes (LVEDVand LVESV, respectively) were calculated
according to Doughty et al [17]. Left ventricular mass index
(LVMI) was calculated as previously described [18]. The
presence of LVH was established when LVMI was >111 g/
m2 for men and >106 g/m2 in women [19]. The following
pulsed Doppler measurements were obtained: maximum
early transmitral velocity in diastole; maximum late trans-
mitral velocity in diastole; the deceleration time of the early
mitral filling wave; and isovolumic relaxation time. Left
ventricular EF was calculated according to Quinones et al.
[20].
2.3. Sample acquisition
Transvenous endomyocardial biopsies were taken from
the middle area of the interventricular septum with a
bioptome, Cordis 960 mm (7F), under fluoroscopic guid-
ance after angiographic examination, as previously reported
[18]. Two biopsies were taken in each intervention. The
biopsy procedure was well tolerated in all cases and no
complications were recorded. The first sample was divided
into two smaller pieces and frozen separately in liquid
nitrogen following different processes for protein or mRNA
obtention. Protein was extracted in lysis buffer (7 mol/L
urea, 2 mol/L thiourea, 4% Chaps, 1% dithiothreitol), and
mRNA was initially isolated with TRIzol (Invitrogen) and
subsequently purified using QIAGEN’s RNeasy Total RNA
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 Isolation kit. The second myocardial sample was immedi-
ately fixed in 4% buffered formalin, embedded in paraffin,
and serially sectioned in 4-Am-thick sections for the
histomorphological studies.
Human liver tissue, kindly provided by Dr. Jose´ Ignacio
Riezu-Boj, was used as a positive control in analyzing the
expression of the two PPARa isoforms. The hepatic
sample was processed in the same way as the cardiac
samples.
2.4. mRNA studies
To identify the presence of the splice variant of PPARa
mRNA, reverse transcription polymerase chain reaction
(RT–PCR) followed by sequentiation was performed.
Reverse transcription was performed with 200 ng of total
RNA and two primers flanking exon 6 were used to
amplify human cDNA: (i) 5V–GCCAGTATTGTCGATTT-
CACAAGT–3V corresponding to sequences 674–697 of
the human PPARa cDNA, located in exon 5; (ii) 5V–
TCCTTGTTCTGGATGCCATTG–3V corresponding to
sequences 996–1016 of the human PPARa cDNA,
located in exon 7. PCR products were separated by
electrophoresis, showing two different fragments, one of
343 bp and other about 140 bp (Fig. 1). The smaller
fragment was excised from the gel and cloned into a pCR
2.1 vector for sequencing. The DNA sequence of this
fragment was determined using the dideoxy chain-termi-
nation method [21]. This fragment contained the pub-
lished sequence of exon 5 followed by exon 7, lacking
exon 6 [22] (Fig. 1).
To corroborate the presence of the truncated PPARa
mRNA, a specific TaqMan fluorescent probe that recognizes
the last nucleotides of exon 5 and the first nucleotides of
exon 7 of PPARa cDNA was designed. The fluorescent
signal of this probe can only be detected when exon 5 is
followed by exon 7, exon 6 being absent. The fluorescent
signal was analyzed with an ABI PRISM 7000 Sequence
Detection System. This splice variant was detected in all
individuals tested.Fig. 1. Left panel: Fragments of 343 bp and of 140 bp obtained by amplification o
Nucleotide sequence of the 140 bp fragment, with the corresponding exons.mRNA levels of the two PPARa isoforms and the
PPARa target genes carnitine palmitoyl transferase-I (CPT-
I) and long-chain 3-hydroxyacyl-CoA dehydrogenase
(LCHAD) [23] were analyzed by real time quantitative
RT–PCR. Reverse transcription was performed with 200 ng
of total RNA. Real-time PCR was performed with an ABI
PRISM 7000 Sequence Detection System by using specific
TaqMan MGB fluorescent probes. Data are expressed as
arbitrary units (AU) relative to constitutive 18S ribosomal
RNA.
2.5. Protein studies
To analyze the expression of both isoforms of PPARa
and RXRa proteins, aliquots containing 10 Ag of total
protein were diluted in 4 sample buffer (40% h-
mercaptoethanol, 8% SDS, 40% glycerol, 0.025% bromo-
phenol blue, and 0.25 mmol/L Tris, pH 6.4), separated by
electrophoresis on 10% polyacrylamide gel and transferred
onto nitrocellulose membranes. To identify the presence of
the truncated PPARa protein a Western blot followed by
an immunoblot using two different antibodies were
performed in every sample. Specific rabbit and goat
polyclonal antibodies (Santa Cruz Technologies) against
the amino-terminal and the carboxy-terminal portions of
PPARa, respectively, were incubated at a dilution of
1:1000. Bands were detected by incubation with peroxi-
dase-conjugated anti-rabbit IgG (Amersham) at a dilution
of 1:5000 and anti-goat IgG (Amersham) at a dilution of
1:50000. Two protein bands were detected using the
antibody against the amino-terminal portion of PPARa:
one of 53 kDa and another of 30 kDa. When the same
membranes were reprobed with antibody against the
carboxy-terminal portion, no signal of 30 kDa was
detected. The two PPARa isoforms (e.g., the native and
the truncated) are therefore expressed in the human
myocardium at the protein level. Since both isoforms of
PPARa have been described in the human liver [14],
hepatic tissue was used as a positive control for the two
antibodies. Western blot of the hepatic tissue showed twof cDNAwith the primers flanking exon 6 and electrophoresis. Right panel:
2
Table 1
Clinical parameters determined in hypertensives
Parameter HT group LVH group HF group
Age, years 63T2 59T2 66T4
Gender, M/F 2/4 6/4 5/3
BMI, kg/m2 24.8T1.6 30.7T2.3 28.4T1.1
Loop diuretics, n 1 1 6
ACEI or ARA, n – – 8
h-Blockers, n – 1 7
a-Blockers, n – 1 –
Ca2+ antagonists, n 1 2 –
SBP, mm Hg 162T8 168T7 146T5
DBP, mm Hg 89T5 94T3 88T3
HR, beats/min 69T4 70T3 69T2
LVEDV, ml 114.76T11.95 122.66T10.49 167.28T15.76a,b
LVESV, ml 34.72T6.65 32.33T4.88 91.32T18.18a,c
LVMI, g/m2 82.1T4.8 151.4T12.0d 145.39T7.8d
IVRT, ms 104.2T2.3 107.1T6.3 109.5T4.3
VE/VA 1.13T0.14 0.78T0.08 1.38T0.37
TDEC, ms 216.7T9.2 226.6T22.3 207.2T19.2
EF, % 73.7T3.1 68.7T1.9 43.9T5.6c,d
HT, hypertension; HF, heart failure; LVH, left ventricular hypertrophy;
BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor;
ARA, angiotensin II type 1 receptor antagonist; SBP, systolic blood
pressure; DBP, diastolic blood pressure; HR, heart rate; LVEDV, left
ventricular end diastolic volume; LVESV, left ventricular end systolic
volume; LVMI, left ventricular mass index; IVRT, isovolumic relaxation
time; VE, maximal early transmitral velocity in diastole; VA, maximal late
transmitral velocity in diastole; TDEC, deceleration time; EF, ejection
fraction.
Values are expressed as meanTS.E.M. or number of subjects.
a p<0.05, compared with HT group.
b p <0.05, compared with LVH group.
c p<0.01, compared with LVH group.
d p<0.01, compared with HT group.
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 bands of 53 kDa and 30 kDa using the amino-terminal
antibody and only one band of 53 kDa with the carboxy-
terminal antibody.
The expression of RXRa was assessed by using a
specific rabbit polyclonal antibody (Santa Cruz Biotechnol-
ogies) at a dilution of 1:1000 and peroxidase-conjugated
anti-rabbit IgG (Amersham) antibody at a dilution of
1:5000.
Both PPARa isoforms and RXRa protein expression
was visualized with the ECL-Plus chemiluminescence
system (Amersham) and autoradiograms analyzed using
an automatic densitometer (Quantity One, Bio-Rad). The
blots were reprobed with a monoclonal h-actin antibody
(Sigma) as a control for loading. Data are expressed as
arbitrary densitometric units (ADU) relative to h-actin
expression.
2.6. Histomorphologic study
We analyzed some myocardial histomorphological alter-
ations involved in the transition from LVH to HF (e.g.
apoptosis, inflammation and fibrosis) in 7 patients from the
LVH group and 8 from the HF group.
Apoptosis was assayed by the terminal deoxynucleo-
tidyl transferase (TdT) reaction. DNA end-labeling
(TUNEL) methodology was performed as previously
described [24]. The discrimination between cardiomyo-
cytes and non-cardiomyocytes was performed according to
cytological characteristics of the different cell types [25].
Apoptotic indexes were calculated as the ratio between
the number of TUNEL positive nuclei and the total
number of nuclei for each type of cardiac cell evaluated.
The determination of the total number of cardiomyocytes
and non-cardiomyocytes was performed on a serial section
from the one employed for the TUNEL technique, stained
with Masson’s trichrome. Cardiomyocyte and non-cardio-
myocyte densities were also analyzed. To asses myocar-
dial inflammation, COX-2 protein expression was
analyzed by immunohistochemistry using a specific goat
polyclonal antibody (Santa Cruz Biotechnologies) at a
dilution of 1:100 and biotinilated anti-goat IgG (Amer-
sham) antibody at a dilution of 1:200. The staining of
myocardial deposit of collagen fibers was performed as
previously reported [18]. The fraction of myocardial
volume occupied by fibrillar collagen (CVF) and COX-2
immunostained area were determined by quantitative
morphometry with an automated image analysis system
(AnalySYS, Soft Imaging System GmbH, Hammer). The
histomorphologic studies were performed by two pathol-
ogists blinded to the other characteristics of the patients
under study.
2.7. Statistical analysis
To analyze the differences among the three groups of
patients, a 1-way ANOVA followed by Scheffe´’s test wasperformed once normality had been proven (Shapiro–
Wilks test); otherwise, the non-parametric Kruskal–Wallis
test followed by a Mann–Whitney U test (adjusting the a-
level by Bonferroni’s inequality) was used. To assess any
tendency in the parameters measured as HHD develops
and progresses, the linear test for trend was used. Differ-
ences between patients with LVH and patients with HF
were tested by a Student’s t test for unpaired data once
normality was demonstrated; otherwise, a non-parametric
test (Mann–Whitney U test) was used. The correlation
between continuously distributed variables was tested by
univariate regression analysis. Values are expressed as
meanTS.E.M. A value of p <0.05 was considered statis-
tically significant.3. Results
3.1. Clinical characteristics of hypertensive patients
The clinical characteristics of the three groups of patients
are presented in Table 1. Two patients in the HT group and
five patients of the LVH group were receiving antihyper-
tensive medication as monotherapy. No significant differ-
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 ences in blood pressure were found between treated and
untreated patients in HT and LVH groups (data not shown).
Most patients in the HF group were treated with the
combination of a loop diuretic, a beta-blocker and either
an angiotensin converting enzyme inhibitor or an angioten-
sin II type 1 receptor antagonist. The values of LVMI were
higher in LVH and HF groups than in the HT group. The EF
was lower in the HF group than in LVH and HT groups. The
left ventricle volumes were higher in the HF group than in
LVH and HT groups.
3.2. Expression of PPARa isoforms and RXRa
Compared with the HT group (1.16T0.24 arbitrary
densitometric units, ADU), the expression of native
PPARa protein was decreased ( p <0.05) in the LVH
group (0.52T0.10 ADU) and the HF group (0.58T0.06
ADU) (Fig. 2). No difference was found in native PPARa
protein expression between LVH and HF groups. The
expression of truncated PPARa protein was higher
( p <0.001) in the HF group (2.95T0.32 ADU) than in
the LVH group (0.89T0.16 ADU) and the HT group
(0.17T0.09 ADU) (Fig. 2). Although the expression of
truncated PPARa protein did tend to be higher in the LVH
group than in the HT group, the differences did not reach
statistical significance. As a consequence, a progressive
decrease ( p for trend <0.01) was observed in the native
PPARa: truncated PPARa ratio among the three groups of
patients (HT: 4.17T1.85 ADU; LVH: 0.78T0.21 ADU;
HF: 0.20T0.01 ADU). No significant differences in the
expression of the two isoforms of PPARa were found
between patients with systolic HF (native PPARa:
0.59T0.04 ADU; truncated PPARa: 2.92T0.55 ADU)Fig. 2. Left panels: Histograms showing the expression of native (53 kDa) and trun
HF groups. Right panel: Representative Western blots obtained in one subject froand diastolic HF (native PPARa: 0.57T0.11 ADU;
truncated PPARa: 2.98T0.42 ADU).
The expression of RXRa protein did tend to be lower in
the HF group (13.98T0.88 ADU) than in the LVH group
(17.08T1.75 ADU) and the HT group (17.59T5.57 ADU)
but the differences did not reach statistical significance.
The expression of native PPARa mRNA was similar in
the three groups of patients (HT:1.01T0.09 AU; LVH:
1.08T0.12 AU; HF: 1.28T0.13 AU). In addition, no
significant changes were observed in the expression of
truncated PPARa mRNA among the three groups of pa-
tients (HT: 0.62T0.09 AU; LVH: 0.43T0.03; HF: 0.62T
0.09 AU).
3.3. Expression of PPARa target genes
As an approach to evaluate whether the observed
differences in the native PPARa:truncated PPARa ratio
were accompanied by changes in PPARa transcriptional
activity, mRNA expression of the PPARa target genes CPT-
I and LCHAD was assessed. A progressive decrease ( p for
trend <0.05) in CPT-I mRNA and LCHAD mRNA was
observed among HT, LVH and HF groups (Fig. 3).
3.4. Assessment of myocardial apoptosis, inflammation and
fibrosis
Data on the measured histomorphological parameters are
presented in Table 2. The HF group showed increased
( p <0.01) cardiomyocyte apoptotic index compared with the
LVH group. The non-cardiomyocyte apoptotic index did
tend to be higher in the HF group than in the LVH group but
the difference was not statistically significant. Whereascated (30 kDa) PPARa protein isoforms in the myocardium of HT, LVH and
m each group. ADU, arbitrary densitometric units.
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Fig. 3. Upper panel: Histograms showing the mRNA expression of the
PPARa target gene CPT-I in the myocardium of HT, LVH and HF groups.
Lower panel: Histograms showing the mRNA expression of the PPARa
target gene LCHAD in the myocardium of HT, LVH and HF groups. AU,
arbitrary units.
Fig. 4. Inverse correlation ( y =8.35x+74.04) between truncated PPARa
protein and ejection fraction (EF) in all patients. ADU, arbitrary
densitometric units.
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 cardiomyocyte density was lower ( p<0.01) in the HF group
than in the LVH group, no differences were observed in
non-cardiomyocyte density between HF and LVH groups.
COX-2 expression was higher ( p <0.05) in the HF group
than in the LVH group. CVF was increased ( p <0.05) in the
HF group compared with the LVH group.
3.5. Correlational analysis
Truncated PPARa protein was inversely correlated with
EF (r=0.652, p <0.01) (Fig. 4) and directly correlated
with LVEDV (r =0.538, p<0.01) and LVESV (r=0.579,
p <0.01) in all patients (Fig. 5). Truncated PPARa protein
was directly correlated with the cardiomyocyte apoptotic
index (r=0.572, p <0.05) and inversely correlated with theTable 2
Myocardial apoptosis, inflammation and fibrosis
Parameter
CM apoptotic index (positive nuclei/106 nuclei)
Non-CM apoptotic index (positive nuclei/106 nuclei)
CM density (nuclei/mm2)
Non-CM density (nuclei/mm2)
COX-2 (%)
CVF (%)
LVH, means left ventricular hypertrophy; HF, heart failure; CM, cardiomyocyte;
Values are expressed as meanTS.E.M.
a p <0.01, compared with LVH group.
b p <0.05, compared with LVH group.cardiomyocyte density (r=0.695, p <0.01) in patients
with HHD (Fig. 6). No significant correlations were found
between the native PPARa protein and the different
parameters tested in this study. CPT-I mRNA expression
was directly correlated with EF (r =0.640, p <0.05).4. Discussion
The main findings of this study can be summarized as
follows: (1) the human heart expresses both the native active
and the truncated inhibitory isoforms of PPARa protein, (2)
whereas the expression of native PPARa protein is
diminished in patients with HHD, the truncated PPARa
protein is overexpressed only in those patients with HHD
who develop HF, (3) the expression of the PPARa target
genes decreases in parallel with the development and
progression of HHD, and (4) the truncated PPARa protein
is associated with the structural, geometric and functional
deterioration of the hypertensive left ventricle.
A variant human PPARa mRNA species has been
identified, which is generated by a post-transcriptional
mechanism involving alternative splicing resulting in theLVH group HF group
2107T781 11215T1722a
2031T567 4177T878
604T50 423T33a
1095T100 1171T69
10.86T1.02 20.84T4.49b
5.47T0.51 8.44T1.19b
COX-2, cyclo-oxygenase 2; CVF, collagen volume fraction.
Fig. 5. Left panel: Direct correlation ( y =17.54x +109.58) between truncated PPARa protein and left ventricular end-diastolic volume (LVEDV) in all patients.
Right panel: Direct correlation ( y =18.75x +24.81) between truncated PPARa protein and left ventricular end-systolic volume (LVESV) in all patients. ADU,
arbitrary densitometric units.
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 skipping of exon 6 [11,12]. This splice variant of PPARa
mRNA has been identified in a number of human tissues,
including the heart [13]. In this study, we detect the PPARa
mRNA variant in all of the individuals examined, which
suggests that exon skipping is associated with the process-
ing of the human PPARa pre-mRNA, and that it does not
reflect a rare allele. Exon skipping has been observed for
transcripts of other genes and often leads to circular RNAs
formed by the excised exons [26]. However, neither the
mechanisms leading to the excision of the exon and the
formation of the circular RNA nor the factors that contribute
to this process have been clearly defined.
Data presented in the current study demonstrate that the
regulation of the two cardiac isoforms of PPARa protein is
altered in a different way in patients with HHD. In fact,
whereas repression of the native PPARa isoform is
associated with the development of LVH, overexpression
of the truncated PPARa isoform seems to be linked to the
transition from LVH to HF. Therefore, although a dimin-
ished expression of native PPARa has been reported
previously in the hypertrophied left ventricle of animals
submitted to cardiac pressure overload [27,28] and patientsFig. 6. Left panel: Direct correlation ( y =2629x +1945) between the expression of
Inverse correlation ( y =78x +663) between the expression of truncated PPARawith HF [29], this is the first demonstration of alterations of
truncated PPARa in the hypertensive heart. In addition, the
origin of these alterations seems to be post-transcriptional
since native and truncated mRNA PPARa expression was
not modified along the three groups of hypertensives tested.
However, further studies are necessary to investigate
potential post-trancriptional mechanisms (e.g. changes in
mRNA stability) influencing the two isoforms of PPARa in
the hypertensive myocardium.
Nevertheless, overexpression of the truncated PPARa
may also be a consequence of the loss of cardiac function. In
fact, generation by alternative splicing of isoforms with
repressive activity on the native isoform has been reported
for other nuclear receptors (i.e., the glucocorticoid receptor
and the thyroid hormone receptor) [30,31] as a general
mechanism to diversify and to adapt receptor action on
pathophysiological conditions. Clearly, further studies are
necessary to elucidate the significance and relevance of
truncated PPARa protein in the hypertensive heart.
As suggested by in vitro studies [14], the association of
diminished active PPARa isoform with enhanced inhibi-
tory PPARa isoform may compromise PPARa-dependenttruncated PPARa protein and cardiomyocyte apoptotic index. Right panel:
protein and cardiomyocyte density. ADU, arbitrary densitometric units.
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 transcriptional activity in the failing heart. In fact, we
observed that a progressive decrease in native PPARa:
truncated PPARa ratio was associated with a progressive
decrease in the expression of the PPARa target genes CPT-
I and LCHAD involved in fatty acid transport and
oxidation. A continuous decrease in fatty acid oxidation
has been found in hypertensives with LVH with and
without HF compared with control subjects [3]. Since ATP
availability and function of the heart are closely linked, it
is reasonable to assume that deactivation of PPARa
leading to diminished fatty acid oxidation and reduced
production of ATP might be involved in the compromise
of cardiac function in HF. In support of this possibility, we
observed a direct association between CPT-I expression
and ejection fraction. Thus it is tempting to speculate that
progressive impairment of PPARa transactivation activity
accompanies the development of HHD and may contribute
to its progression to HF.
Alternatively, PPARa alterations could be involved in the
transition from LVH to HF through the facilitation of some
structural features characteristic of myocardial remodelling.
In fact, a number of experimental evidences suggest that
depressed myocardial PPARa expression and/or activity
could be linked with the development of inflammation and
fibrosis [7–10]. In addition, it has been shown that PPARa-
null mice develop massive cardiomyocyte accumulation of
fatty acid intermediates [5]. Some of these compounds, e.g.
ceramide, can induce reactive oxygen species accumulation,
inducible nitric oxide synthase expression and cardiomyo-
cyte apoptosis [32]. Our findings showing associations of
depressed PPARa activity with increased inflammation,
fibrosis and cardiomyocytes apoptosis in the failing
hypertensive heart could provide support to this view.
Furthermore, the associations here reported of truncated
PPARa with cardiomyocyte apoptosis and density on the
one hand, and left ventricular dimensions and systolic
performance on the other hand, raise the possibility that this
molecule might contribute directly to the development of
HF in hypertensive patients. In fact, it has been proposed
that increased cardiomyocyte apoptosis present in the failing
hypertensive heart could contribute to the impairment of
systolic function due to the loss of contractile mass, and to
the dilatation of the left ventricular chamber through side-to-
side slippage of cardiomyocytes [33,34].
4.1. Limitations of the study
This was a study involving a small number of patients.
Furthermore, no studies in normotensive subjects were
performed. However, because of the nature of the goals
under investigation this design is appropriate. In addition,
it must be recognized that therapy with different types of
drugs in the three groups of patients may have confounded
the findings and their interpretation. For instance, angio-
tensin converting enzyme inhibitors have been reported to
interfere with PPARa expression in the vascular wall [35]although no data are available yet on their effects on
cardiac PPARa. Nevertheless, one must consider that,
since such therapies are standard for hypertension and HF,
it would have been unreasonable to withdraw them for the
purposes of this research. Moreover, it is important to note
that no patient was under treatment with drugs that modify
PPARa expression and/or activity (i.e., thiazolidinediones,
fibrates and statins). We performed biopsies of the right
side of the interventricular septum to assess the molecular
and cellular effects of left ventricular pressure loading.
However, as shown by others [36], lesions present in the
septum in postmortem tissue from hypertensive human
hearts are representative of lesions existing in the free wall.
Finally, we are aware that the real time RT–PCR method
here used is not sensitive enough to detect small mRNA
differences. However, the small amount of mRNA
available in the samples forced us to select this method
for mRNA expression measurement.
In summary, we report for the first time that HHD is
associated with an excess of the truncated inhibitory PPARa
isoform related to the native active isoform, which is
accompanied by a diminished expression of a PPARa target
enzymes involved in fatty acid utilization. Interestingly,
these alterations evolve in parallel with both the develop-
ment myocardial structural remodelling and the progression
from compensated LVH to HF. In addition, results here
presented suggest that the truncated PPARa isoform may be
directly involved in the pathophysiology of the hypertensive
left ventricle. Albeit preliminary and descriptive in nature,
the data here presented set the stage for further studies
intended to test the above hypothesis.Acknowledgements
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